Revolution Medicines (NasdaqGS:RVMD) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Speaker15Good day, and thank you for standing by. Welcome to Revolution Medicines' fourth quarter 2025 earnings conference call. After the speaker's presentation, there will be a question-and-answer session. To ask a question during your session, you will need to press star 11 on your telephone. You will then hear an automated message advising that your hand is raised. To withdraw your question, please press star 11 aga ...

ACADIA Pharmaceuticals (NasdaqGS:ACAD) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Speaker11Thank you for standing by. My name is J.L., and I will be your conference operator today. At this time, I would like to welcome everyone to the ACADIA Pharmaceuticals Inc. fourth quarter earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press s ...

Group 1 - The article discusses the Biotech Analysis Central service, which provides in-depth analysis of pharmaceutical companies and offers a model portfolio of small and mid-cap stocks [1][2] - The service includes over 600 articles on biotech investing, live chat, and various analysis and news reports to assist healthcare investors [2] - A promotional offer is available for new subscribers, including a two-week free trial and a discounted annual subscription price [1] Group 2 - The previous discussion on Equillium (EQ) focused on its drug candidate EQ504 for ulcerative colitis (UC) [2] - The author emphasizes the importance of utilizing an applied science background to generate long-term value in the healthcare sector [2]

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Corcept Therapeutics Incorporated common stock during the specified Class Period, indicating potential legal recourse for affected investors [1]. Group 1: Class Action Details - The class action lawsuit is for purchasers of Corcept common stock between October 31, 2024, and December 30, 2025, inclusive [1]. - Investors who purchased shares during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly [3][6]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company and has recovered hundreds of millions for investors [4]. Group 3: Case Background - The lawsuit alleges that Corcept misrepresented the status of its New Drug Application (NDA) for relacorilant, claiming strong support from clinical trials while the FDA had raised concerns about the evidence [5]. - Defendants reportedly assured investors that there were no impediments to NDA approval, despite known risks that it might not be approved [5].

Successfully transitioned into a fully integrated commercial-stage company following the first two independent launches of TRYNGOLZA and DAWNZERA. Performance attribution for TRYNGOLZA was driven by a compelling clinical profile and strong execution, exceeding expectations with $108 million in full-year revenue. Achieved breakthrough Phase III results for olezarsen in severe hypertriglyceridemia, demonstrating an unprecedented 85% reduction in acute pancreatitis events. Strategic positioning in neur ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced today the U.S. Food and Drug Administration (FDA) approval of NUMELVI™ (atinvicitinib tablets) – the first and only second-generation Janus kinase (JAK) inhibitor indicated for the control of pruritus associated with allergic dermatitis in dogs six months of age and older. The product is expected to b. ...

Fourth Quarter and Full Year 2025 Earnings Call February 25, 2026 Call Agenda Catherine Owen Adams Chief Executive Officer Welcome Commercial Update Tom Garner Executive Vice President, Chief Commercial Officer Elizabeth H.Z. Thompson, Ph.D. Executive Vice President, Head of Research and Development R&D Update Financial Update Mark Schneyer Executive Vice President, Chief Financial Officer Al Kildani Senior Vice President, IR and Corporate Communications CEO Opening Remarks Closing Remarks Catherine Owen Ad ...

Core Insights - United Therapeutics Corporation reported fourth-quarter results that exceeded earnings expectations but fell short on revenue, leading to a more than 9% increase in shares intra-day [1] Financial Performance - Adjusted earnings per share for the fourth quarter were $7.70, surpassing the consensus estimate of $7.10 by $0.60 [1] - Revenue for the fourth quarter totaled $790.2 million, below expectations of $815.24 million, but represented a 7% increase from $735.9 million in the prior-year quarter [2] - Full-year 2025 revenue reached a record $3.18 billion, up 11% from 2024 [2] Product Revenue Breakdown - Total Tyvaso revenue grew 12% to $464.3 million in the fourth quarter, driven by Tyvaso DPI, which increased 24% to $338.6 million [3] - Growth in Tyvaso revenue was attributed to higher quantities sold due to continued patient expansion and increased commercial utilization linked to Medicare Part D redesign under the Inflation Reduction Act [3] - Orenitram revenue rose 12% to $121.2 million [3] Net Income and Future Outlook - Net income for the quarter reached $364.3 million, or $7.70 per diluted share, compared to $301.3 million, or $6.19 per diluted share, in the fourth quarter of 2024 [4] - For full-year 2025, net income totaled $1.33 billion, up from $1.20 billion in 2024 [4] - Management indicated that the ADVANCE OUTCOMES and TETON-1 clinical programs are expected to deliver pivotal data that could expand treatment options [4]

Corbus Pharmaceuticals (NasdaqCM:CRBP) FY Conference February 25, 2026 03:20 PM ET Speaker0Afternoon, everyone, welcome back to Oppenheimer's 36th Annual Healthcare Conference. I'm Jeff Jones, one of the biotech analysts on the team here, I'm delighted to welcome Yuval Cohen, CEO of Corbus Pharmaceuticals. Well, I can talk. Good afternoon, Yuval. How are you?Speaker1Hello, Jeff. How are you?Speaker0Good. Thank you for joining us today. It's, you know, a great way to kick off an exciting 2026 for you guys.Sp ...

SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Corcept Therapeutics Incorporated (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025, both dates inclusive (the “Class Period”), have until April 21, 2026 to seek appointment as lead plaintiff of the Corcept class action lawsuit. Captioned Allegheny County Employees’ Retirement System v. Corcept Therapeutics Incorporated, No. 26-cv-01525 (N.D. Cal.), the Corcept cla ...